



Narhex Life Sciences Ltd

Level 24, 44 St George's Terrace
PERTH WA 6000
P: +61-8-6211 5099
F: +61-8-9218 8875

ABN: 51 094 468 318

24 March 2015

Company Announcements Office
Australian Securities Exchange
10th Floor
20 Bond Street
SYDNEY NSW 2000.

Dear Sir

SHARE ISSUE & SECTION 708A NOTICE

Narhex Life Sciences Limited ("**Company**") has issued 60,000,000 Shares at \$0.005 raising \$300,000 under Tranche 2 of the Placement pursuant to the Share Sale Agreement for the acquisition of 100% of ResApp Diagnostics Pty Ltd.

An additional 10,000,000 Shares and 35,000,000 free attaching options exercisable at \$0.01 and expiring on 31 December 2016 (on the basis of one option for every 2 shares subscribed for) will be issued under Tranche 2 of the Placement subject to Shareholder Approval.

The Company gives notice pursuant to Section 708A(5)(e) of the Corporations Act that the shares issued on 24 March 2015 were issued without disclosure under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act. The Company, as at the date of this notice, has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company and Section 674 of the Corporations Act. There is no excluded information to be disclosed for the purposes of Sections 708A(7) and (8) of the Corporations Act.

Yours faithfully

Nicki Farley
Company Secretary